Nalaganje...
Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms
BACKGROUND: Inflammatory bowel disease (IBD) afflicts 5 million people and is increasing in prevalence. There is an unmet clinical need for safer and effective treatments for IBD. The BT-11 is a small molecule oral therapeutic that ameliorates IBD by targeting lanthionine synthetase C-like 2 (LANCL2...
Shranjeno v:
| izdano v: | Inflamm Bowel Dis |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6241665/ https://ncbi.nlm.nih.gov/pubmed/29718324 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy167 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|